Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLVE – Evaluation Of Cinacalcet HCl Therapy to Lower Cardiovascular Events
2006-002075-40Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) comparing Cinacalcet arm with Placebo arm (2 arms). Primary endpoint: Composite of all-cause mortality or first non-fatal cardiovascular event. Started Jun 2006; status: completed.
02
Drugs
cinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2006-002075-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002075-40.